# FDA recall D-0774-2022

> **Mylan Pharmaceuticals Inc** · Class II · drug recall initiated 2022-04-07.

## Product

Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV  26505 U.S.A., NDC 67457-445-60

## Reason for recall

Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.

## Distribution

Nationwide in the USA

## Key facts

- **Recall number:** D-0774-2022
- **Recalling firm:** Mylan Pharmaceuticals Inc
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2022-04-07
- **Report date:** 2022-04-27
- **Termination date:** 2023-05-23

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Morgantown, WV, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0774-2022

## Citation

> AI Analytics. FDA recall D-0774-2022. Retrieved 2026-06-02 from https://api.ai-analytics.org/recall/D-0774-2022. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*